Valuation: Polaris Group

Market Cap 10.58B 327M 287M 265M 244M 460M 31.57B 468M 3.17B 1.24B 15.45B 1.23B 1.2B 53.22B P/E 2024
-13.6x
P/E 2025 -6.1x
Enterprise Value 11.09B 343M 301M 278M 256M 483M 33.12B 491M 3.33B 1.3B 16.2B 1.29B 1.26B 55.82B EV / Sales 2024
318x
EV / Sales 2025 603x
Free-Float
37.54%
Yield 2024 *
-
Yield 2025 -
1 day+0.82%
1 week-5.38%
Current month-9.23%
1 month-9.89%
3 months-34.57%
6 months-61.62%
Current year-60.45%
1 week 12.05
Extreme 12.05
12.9
1 month 12.05
Extreme 12.05
14.35
Current year 12.05
Extreme 12.05
35.95
1 year 12.05
Extreme 12.05
44.55
3 years 12.05
Extreme 12.05
91.1
5 years 12.05
Extreme 12.05
232
10 years 9.5
Extreme 9.5
232
Manager TitleAgeSince
Director of Finance/CFO - 01/03/2019
Chief Operating Officer - 01/02/2019
Chief Executive Officer - 01/05/2014
Director TitleAgeSince
Director/Board Member 78 -
Chairman 64 24/11/2014
Director/Board Member 75 25/02/2020
Change 5-day change 1-year change 3-year change Capi.($)
+0.82%-5.38%-67.50%-85.94% 324M
-0.49%-4.01%+0.61%+2.28% 49.18B
-0.87%+0.54%+381.39%+589.60% 39.58B
+0.34%+2.68%+6.92%+61.81% 34.69B
-0.59%-1.08%+29.15%-9.31% 34.42B
-1.82%-1.48%+0.52%+32.02% 27.11B
-1.83%-3.25% - - 16.21B
-0.56%+0.99%+73.35%+116.87% 15.36B
+1.17%+2.30%+15.46%+18.26% 14.05B
-2.11%+0.18%+19.17%-32.74% 13.02B
Average -0.54%-0.11%+51.01%+76.98% 24.39B
Weighted average by Cap. -0.55%-0.38%+78.83%+121.79%

Financials

2024 2025
Net sales 107M 3.31M 2.9M 2.68M 2.47M 4.66M 319M 4.73M 32.09M 12.58M 156M 12.44M 12.17M 538M 40.6M 1.26M 1.1M 1.02M 937K 1.77M 121M 1.8M 12.18M 4.77M 59.3M 4.72M 4.62M 204M
Net income -2.5B -77.47M -67.9M -62.77M -57.73M -109M -7.47B -111M -751M -294M -3.66B -291M -285M -12.59B -3.93B -122M -107M -98.49M -90.59M -171M -11.72B -174M -1.18B -462M -5.74B -456M -447M -19.76B
Net Debt 9.19M 285K 249K 231K 212K 400K 27.44M 406K 2.76M 1.08M 13.43M 1.07M 1.05M 46.26M 517M 16M 14.02M 12.96M 11.92M 22.5M 1.54B 22.86M 155M 60.76M 755M 60.08M 58.77M 2.6B
Logo Polaris Group
The Polaris Group, LLC is a Cayman Islands-based company, which is primarily engaged in biotechnology services, drug testing, contract development and manufacturing services and research, development, manufacture and sales of new drugs. The Company’s core research is ADI-PEG 20, which is undergoing human clinical trials for various cancer indications. The ADI-PEG 20 is a biologic in late-stage clinical development for a wide range of cancers, including hepatocellular carcinoma, mesothelioma, pancreatic cancer, non-small cell lung cancer, melanoma, acute myeloid leukemia, and others. ADI-PEG 20 is a biological drug produced by coupling arginine deiminase and polyethylene glycol with a molecular weight of 20,000.
Employees
-
Date Price Change Volume
20/07/26 NT$12.30 +0.82% 853,571
17/07/26 NT$12.20 -4.69% 1,333,703
16/07/26 NT$12.80 +2.40% 673,380
15/07/26 NT$12.50 +2.04% 804,770
14/07/26 NT$12.25 -2.39% 1,431,018
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
B
  1. Stock Market
  2. Stocks
  3. 6550 Stock